Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Blend (12mg)

Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Peptide Blend

The Tesamorelin, CJC-1295 (Mod GRF 1-29), and Ipamorelin peptide blend is a combination of compounds investigated for their potential interaction with receptors in the pituitary gland. This blend may activate the pituitary cells responsible for growth hormone (hGH) production.

Tesamorelin is a synthetic peptide proposed to function as an analog of growth hormone-releasing hormone (GHRH).[1] It may potentially interact with specific receptors in the pituitary and hypothalamus — designated GHRH receptors — with activation of these receptors appearing to stimulate growth hormone release from pituitary cells.

Mod GRF (Modified Growth Hormone-Releasing Factor), also known as CJC-1295 without DAC (Drug Affinity Complex), is a synthetic peptide analog of endogenous growth hormone-releasing hormone (GHRH).[2] It represents a tetrasubstituted version of the shortest biologically active GHRH sequence and may potentially engage GHRH receptors — specifically GRF (1-29). The peptide appears to bind to GHRH receptors on pituitary cells associated with hGH release.

Ipamorelin is an additional synthetic peptide proposed to interact with pituitary cells, though through a distinct receptor pathway — specifically the growth hormone secretagogue (GHS) receptor.[3] These receptors, also referred to as ghrelin receptors, are found in both the pituitary and hypothalamus. Through activation of these receptors in the brain, Ipamorelin may potentially stimulate hGH synthesis by pituitary cells.

Tesamorelin Specifications

Molecular Formula: C₂₂₁H₃₆₆N₇₂O₆₇S

Molecular Weight: 5136 g/mol

Sequence: trans-hexenoyl-acid-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-AsnSer-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-LeuGln-Asp-Ile-Met-Ser-Arg-GlnGln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu

CJC-1295 (Mod GRF 1-29) Specifications

Molecular Formula: C₁₅₂H₂₅₂N₄₄O₄₂

Molecular Weight: 3367.954 g/mol

Sequence: YDADAIFTQSYRKVLAQLSARKL LQDILSR-NH2

Ipamorelin Specifications

Molecular Formula: C₃₈H₄₉N₉O₅

Molecular Weight: 711.868 g/mol

Sequence: Aib-His-D-2Nal-D-Phe-Lys

Tesamorelin & CJC-1295 (Mod GRF 1-29) & Ipamorelin Research

Tesamorelin, CJC-1295 (Mod GRF 1-29), and Ipamorelin — Structural Modifications

The Tesamorelin, Mod GRF, and Ipamorelin blend appears to act primarily via GHRH receptors in the central nervous system — particularly somatotroph cells found in the anterior pituitary gland — with Tesamorelin and Mod GRF serving as the two principal activators of these receptors.

Tesamorelin’s affinity for GHRH receptors stems from its 44-amino acid chain, which incorporates the specific sequence of GHRH. The peptide additionally carries an acetyl group (CH3CO-) at its N-terminus, potentially enhancing its stability and observed activity, while its C-terminus has been modified with a trans-3-hexenoic acid group — an omega-amino acid modification hypothesized to improve resistance to enzymatic degradation.

Mod GRF’s GHRH receptor affinity derives from its structural similarity to the shortest functional portion of GHRH — GHF (1-29) — with modifications at four positions. At position two, alanine (Ala) is substituted with D-Alanine (D-Ala), potentially increasing enzymatic degradation resistance and stability. At position eight, asparagine (Asn) is replaced with lysine (Lys), potentially enhancing binding affinity to the GHRH receptor. At position fifteen, histidine (His) is substituted with D-Phenylalanine (D-Phe), potentially improving stability and enzymatic resistance. Finally, at position twenty-seven, cysteine (Cys) is replaced with N-methylglycine (Sar), potentially extending the peptide’s half-life by protecting it from enzymatic cleavage.

Tesamorelin, CJC-1295 (Mod GRF 1-29), and Ipamorelin — GHRH Receptor Activation

Tesamorelin and CJC-1295 (Mod GRF 1-29) may potentially interact with GHRH receptors through complex molecular mechanisms involving subsequent activation of intracellular signaling pathways.[4] Upon binding to the GHRH receptor, these peptides may induce conformational changes in receptor structure, potentially engaging downstream signaling cascades.[5]

Tesamorelin and Mod GRF are speculated to stimulate cyclic adenosine monophosphate (cAMP) production within target cells through activation of adenylate cyclase — the enzyme converting ATP to cAMP. Elevated cAMP levels are believed to activate protein kinase A (PKA), a key intracellular signaling molecule that may phosphorylate various target proteins and initiate downstream cellular responses. This proposed GHRH receptor activation and cAMP-PKA cascade may stimulate hGH synthesis and secretion from anterior pituitary somatotrophs, with released hGH additionally influencing insulin-like growth factor-1 (IGF-1) synthesis.[6] Scientists have noted that IGF-1 may exert a “GH independent growth stimulating effect, which with respect to cartilage cells is possibly optimized by the synergistic action with GH,” with IGF-1 considered the primary mediator of GH’s anabolic effects.

Tesamorelin, CJC-1295 (Mod GRF 1-29), and Ipamorelin — GHS Receptor Activation

The blend may also interact with GHS receptors through Ipamorelin’s proposed mechanism of action. Researchers suggest Ipamorelin exhibits receptor selectivity, targeting the GHS receptor without significant cross-reactivity with other receptor types.[7] Scientists noted that “very surprisingly, Ipamorelin did not [appear to] release ACTH or cortisol in levels significantly different from those observed following GHRH stimulation.” This selectivity may allow Ipamorelin to potentially stimulate growth hormone release without necessarily triggering cortisol or ACTH secretion — hormones associated with stress responses and various metabolic and immune functions.

In vitro studies suggest that GHS receptor engagement by Ipamorelin may activate somatotroph cells in the anterior pituitary and initiate intracellular signaling pathways,[8] with one proposed route involving phospholipase C (PLC) activation leading to release of inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 may trigger calcium ion (Ca2+) release from intracellular stores while DAG may activate protein kinase C (PKC), with the resulting intracellular calcium elevation and PKC activation potentially contributing to exocytosis of growth hormone-containing vesicles.

Tesamorelin, CJC-1295 (Mod GRF 1-29), and Ipamorelin — Growth Hormone Synthesis

Research suggests all three peptides may potentially stimulate substantial growth hormone release from anterior pituitary cells. Tesamorelin exposure was associated with a 69% increase in total growth hormone levels as assessed by area under the curve (AUC) methodology, alongside a possible 55% rise in average growth hormone pulse area. The peptide does not appear to significantly influence pulse frequency or peak growth hormone concentrations. IGF-1 levels also appeared to increase by 122% during Tesamorelin testing.[9]

A modified CJC-1295 analog evaluated over a 16-week study appeared to influence growth hormone and IGF-1 levels — with findings suggesting potential growth hormone release enhancement of 70% to 107% over 12 hours from anterior pituitary somatotrophs, alongside an approximately 28% increase in IGF-1 levels.[10] Ipamorelin, based on experimental data, may additionally elevate growth hormone secretion to approximately 80 mIU/l — appearing to exceed placebo levels by approximately 60-fold.[11]

Tesamorelin, CJC-1295 (Mod GRF 1-29), and Ipamorelin — Skeletal Muscles

In the referenced 16-week study, the partially modified CJC-1295 analog was observed to increase skeletal muscle mass and water retention in test models, with a total weight increase of 2.78 pounds (1.26 kg) recorded. These effects are thought to be associated with changes in growth hormone and IGF-1 levels, with researchers additionally noting a significant increase in epidermal layer thickness — potentially reflecting elevated growth hormone’s influence on epidermal cell proliferation.[10]

Regarding Tesamorelin, a CT scan-based study investigated its potential effects on muscle tissue structural quality.[12] Findings suggested a possible association between Tesamorelin and improvements in muscle tissue density and volume — particularly in the rectus abdominis, psoas major, and paraspinal muscles — alongside reductions in intramuscular fat content relative to controls.

Further research in murine Ipamorelin models proposed potential for muscle tissue anabolism through nitrogen balance restoration and reduced nitrogen wasting,[13] hypothesized to result from Ipamorelin’s modulation of growth hormone and IGF-1 production. Studies assessed hepatic urea nitrogen (CUNS) generation as an indicator of nitrogen metabolism efficiency, alongside overall nitrogen homeostasis and theoretical tissue nitrogen distribution. Results suggested Ipamorelin may reduce CUNS by approximately 20% under induced catabolic conditions, with a potential decrease in urea cycle enzyme expression also observed — implying possible nitrogen balance re-establishment and modification of nitrogen levels across tissues.

Tesamorelin, CJC-1295 (Mod GRF 1-29), and Ipamorelin — Appetite Signaling

Ipamorelin appears to influence pituitary cells through GHS receptors — the same receptor class activated by the hunger-associated hormone ghrelin in animal models. It is therefore speculated that Ipamorelin may influence food consumption through ghrelin receptor interaction in the nervous system.[14] Researchers hypothesize that ghrelin receptor activation may enhance hunger signals, potentially contributing to increased body mass. In certain experimental investigations, Ipamorelin-exposed animal subjects exhibited an approximately 15% rise in body weight, theorized to be potentially linked to increased adipose tissue relative to overall body composition.

Dual-energy X-ray absorptiometry (DEXA) scans used to assess bone mineral density and body composition may suggest an elevated fat percentage potentially associated with Ipamorelin. Researchers accordingly propose that growth hormone secretagogues such as Ipamorelin may elevate fat levels through growth hormone-independent mechanisms, potentially including enhanced food intake.

Tesamorelin, CJC-1295 (Mod GRF 1-29), and Ipamorelin — Visceral Adiposity

Research studies have observed reductions in visceral adiposity in Tesamorelin-exposed models.[15] One study noted a 4.7% decrease in absolute hepatic fat in Tesamorelin-exposed subjects with no change in controls — representing a relative liver fat reduction of 37% and suggesting a possible benefit in attenuating liver fat accumulation. Additionally, 35% of the Tesamorelin group achieved a hepatic fat fraction below 5% compared to just 4% in controls.

Regarding liver tissue fibrosis, Tesamorelin appeared to slow progression, with 10.5% of the Tesamorelin group showing fibrosis advancement compared to 37.5% in the placebo group — though pre-existing fibrosis did not appear to improve significantly. The reduction in liver fat correlated with fibrosis improvements, suggesting a potential mechanistic link between decreased liver fat and attenuated fibrosis progression. Tesamorelin also appeared to demonstrate anti-inflammatory properties as suggested by reduced C-reactive protein (CRP) levels.

Despite these findings, Tesamorelin did not significantly affect liver enzymes including alanine aminotransferase (ALT) and gamma-glutamyl transferase (GGT) overall, though ALT was reduced in subjects with elevated baseline values. Fasting glucose and hemoglobin A1c remained largely unchanged, suggesting a neutral effect on glucose regulation during the study period.

In a study spanning over 52 weeks and involving more than 800 models, the peptide potentially produced a mean visceral adiposity reduction of -17.5%, alongside apparent reductions in triglycerides of a mean -48 mg/dl, cholesterol of a mean -8 mg/dl, and non-high-density lipoprotein of a mean -7 mg/dl.[16] Further reviews across multiple Tesamorelin experiments have indicated a potential visceral fat reduction of up to -25%.[17]

Disclaimer: The products mentioned are not intended for human or animal consumption. Research chemicals are intended solely for laboratory experimentation and/or in-vitro testing. Bodily introduction of any sort is strictly prohibited by law. All purchases are limited to licensed researchers and/or qualified professionals. All information shared in this article is for educational purposes only.

References